Type of information: Production agreement
Company: ViGeneron (DE) WuXi Advanced Therapies (USA - PA)
Therapeutic area: Ophthalmological diseases
Type agreement: development manufacturing
Action mechanism: gene therapy. VG901 targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no approved treatment option. VG901 is developed from ViGeneron’s proprietary next generation vgAAV vector platform that allows a superior transduction of retinal cells and intravitreal, a less invasive treatment administration.
Disease: retinitis pigmentosa